 The primary objective is to compare the antiviral efficacy of an early switch from a boosted PI2NRTI regimen to Trizivir after undetectability of HIV-RNA has been achieved on 2 consecutive occasions with uninterrupted use of the PI2NRTI regimen for 96 weeks. 